Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis

• Main Authors: Jiaqi Wu, Qingsheng Zhang, Guanghui Yan, Xianhui Jin
• Format: Article
• Language: English
• Published: BMC 2018-08-01
• Series: Journal of Orthopaedic Surgery and Research
• Subjects: Denosumab; Bisphosphonates; Fracture; Meta-analysis
• Online Access: http://link.springer.com/article/10.1186/s13018-018-0865-3

Abstract Background The standard treatment for osteoporosis was controversial. Denosumab and bisphosphonates were two most common drugs. The purpose of this study was to compare the efficacy and safety of denosumab with bisphosphonates to treat osteoporosis. Methods Published literatures, only including randomized controlled trials (RCTs), were searched in the following electronic databases: PubMed, Embase, Web of Science, Cochrane Library, and Google database from inception to April 20 2018. Studies that compared denosumab with bisphosphonates to treat osteoporosis were included. Random-effect model was used for meta-analysis due to the unavoidable clinical heterogeneity. We used the risk of fracture as the primary outcome. Stata 12.0 was used for meta-analysis. Results Eleven studies involving 5446 patients (denosumab = 2873, bisphosphonates = 2573) were included in the present meta-analysis. There was no significant difference between the risk of fracture (risk ratio (RR), 1.13; 95% confidence interval (CI), 0.82–1.55; P = 0.466), adverse events (AEs) (RR 1.00; 95% CI 0.96–1.04; P = 0.957) and withdrawn due to AEs (RR 0.68; 95% CI 0.34–137; P = 0.280). Denosumab compared with bisphosphonates significantly increased change in total hip, femoral neck, lumbar spine, and one-third radius bone mineral density (BMD) for postmenopausal osteoporosis patients (P < 0.05). Conclusions Our meta-analysis suggested that denosumab but not bisphosphonates significantly increased change in total hip, femoral neck, lumbar spine, and one-third radius BMD for postmenopausal osteoporosis patients. Current evidence suggested no benefit of denosumab for reducing risk of fracture than bisphosphonates. More long-term follow-up RCTs are needed to identify the potential complications of denosumab.